IVF

SCHEDULE 13G - INVO Fertility, Inc. (0001417926) (Subject)

NT 10-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on March 27, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on March 27, 2026, the Company's common stock will trade on a post-split basis under the same trading symbol, "IVF". As a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F880. As a result of the reverse stock split, every 5 shares of issued and out

SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced the adoption of time-lapse incubation technology at its Wisconsin clinic. This integration reflects INVO's commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to investing in laboratory excellence and clinical quality across its growing network of clinics. "INVO Fertility is proud to introduce this te

MIDDLETON, Wis. and SARASOTA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that its Wisconsin Fertility Institute (WFI) clinic has joined the Progyny network. Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI's participation in the Progyny network significantly expands the clinic's acce

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025. Founded more than a decade ago, Family Beginnings has built a strong reputation for delivering compreh

424B3 - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040. INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilizatio

EFFECT - INVO Fertility, Inc. (0001417926) (Filer)

S-8 - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today issued a shareholder letter from its Chief Executive Officer, Steve Shum, outlining the Company's strengthened fundamental position and its strategic outlook for continued growth. In the letter, management highlights meaningful progress across operations, acquisitions, and capital structure, positioning INVO Fertility for growth through both organic initiatives and strategic clinic acquisitions. Dear Fellow Shareholders, As

S-1 - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. ("INVO" or the "Company") (NASDAQ:IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the "December 2025 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding December 2025 Warrants to an amended exercise price of $1.59, and to exercise the outstanding December 2025 Warrants to purchase an aggregate of 4,733,728 shares of the Company's common s

8-K - INVO Fertility, Inc. (0001417926) (Filer)

3 - INVO Fertility, Inc. (0001417926) (Issuer)

SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit, taking place virtually on Thursday, January 15, 2026. The webcast will take place at 3:00 p.m. ET on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/ivf. A replay will also be avai

8-K - INVO Fertility, Inc. (0001417926) (Filer)

424B4 - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced changes to its executive leadership team to align its human resources with the Company's growth strategy focused on the acquisition and establishment of fertility clinics and ancillary organizations. Terah Krigsvold, who has served as INVO's controller since December 2020, has been appointed as the Company's new chief financial officer, replacing Andrea Goren. Mr. Goren, who has served as INVO chief financial officer

DEFA14A - INVO Fertility, Inc. (0001417926) (Filer)

EFFECT - INVO Fertility, Inc. (0001417926) (Filer)

DEF 14A - INVO Fertility, Inc. (0001417926) (Filer)